The above unaudited financial results were reviewed by the Audit Committee and have been approved by the Board at its meeting held on January 30, 2010. The quarterly stand alone results are subject to Limited Review by Auditors of the Company.

The Consolidated financial results, which are optional, have been presented by the Company, so as to provide additional information.

The consolidated financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement', AS-27 ' Financial Reporting of Interests in Joint Ventures' and includes financial results of all subsidiaries and Joint Ventures.

Investor complaints pending at the beginning of the quarter: Nil, received: 40, resolved: 40 and lying unresolved at the end of the quarter Nil.

Foreign Exchange (Gain)/Loss represents exchange differences arising on all foreign currency transactions. This includes Gain during the quarter due to restatement of Foreign Currency Convertible Bonds (net of Deposits) Rs.2977 lakhs (Loss 3930 lakhs).

In respect of a matter referred to in the limied review report by the Auditor for the quarter and six months ended September 30, 2009 relating to non - provision of premium of Rs. 29519 lakhs on redemption of outstanding USD 192.80 Million Zero Coupon Foreign Currency Convertible Bonds (FCCBs), the management is of the opinion that the determination and crystallisation of liability is dependent upon the outcome of uncertain future events or actions, not wholly within the control of the Company and therefore the same has been considered as a "contingent liability" as at September 30, 2009. Further, the management continues to hold the same view as at December 31, 2009 on outstanding USD 178.05 Million FCCBs, which excludes USD 13.75 Million FCCBs deposited for conversion but pending for alottment into Equity as at December 31, 2009.

The paid up share capital of the Company has increased to Rs.2757.07 lakhs as a result of:
a) Allotment of 150030 Equity Shares of Rs. 5 each at a premium of Rs. 357.60 per share under ESOP 2004 Scheme by the Compensation Committee of the Company at their meeting held on December 15, 2009.
b) Allotment of 83121 and 1142920 Equity Shares of Rs.5 each for cash at premium of Rs. 517.036 by the the Committee of Board of Directors of the Company on November 4, 2009 and January 6, 2010 respectively upon request for conversion of FCCBs worth USD 14.75 Million out of USD 60 Million issue in terms of the offer document.

During November 2009, the Company has incorporated a new step down subsidiary Aurobindo ILAC Sanayi ve Ticaret Limited Sirketi in Turkey.

The scheme of arrangement under Sections 391 to 393 read with Sections 100 to 103 of the Companies Act, 1956, for utilization of capital profit on buy back of FCCBs, balance in capital redemption reserve account to adjust certain expenses as defined in the Scheme, filed with the Honourable High Court of Andhra Pradesh in June 2009 has been dismissed.  Accordingly the capital profit on buyback of FCCBs aggregating to Rs 219 lacs has been taken to Profit & Loss account as an exceptional item

The Board of Directors of the Company proposed a scheme under Sections 391 to 394 of the Companies Act, 1956 ('the Scheme') for amalgamation of Trident Life Sciences Limited ('Trident'), a wholly owned subsidiary of the Company. The Scheme provides for amalgamation of Trident with the Company from October 1, 2009 ('the appointed date').  Pending such approval, no adjustments have been made to the financial results for the period ended December 31, 2009.

The Board in its meeting held on January 30, 2010 has approved an interim dividend of 60% i.e Rs.3/- per equity share of Rs.5/- each for the current financial year 2009-10. Consequently, the total amount of interim dividend payable would be Rs.1656 Lakhs.

Figures for the previous periods/year have been rearranged/regrouped wherever necessary to make it comparable.